INDACATEROL MALEATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H28N2O3.C4H4O4
Molecular Weight	508.564
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCc1cc2CC(Cc2cc1CC)NC[C@@]([H])(c3ccc(c4c3ccc(n4)O)O)O.C(\[H])(=C(\[H])/C(=O)O)/C(=O)O

InChI

InChIKey=IREJFXIHXRZFER-PCBAQXHCSA-N

InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-2 adrenergic receptor 197 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514	Agonist 2456	76.0 nM [Ki]
Beta-1 adrenergic receptor 157 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218	Agonist 2456	91.4 nM [Ki]
Beta-2 adrenergic receptor 197 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514	Agonist 2456	76.0 nM [Ki]
Beta-1 adrenergic receptor 157 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218	Agonist 2456	91.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf	Primary		Approved 7997	ARCAPTA NEOHALER Approved Use UTIBRONTM NEOHALER® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use: UTIBRON NEOHALER is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.2) Launch Date 1.30947835E12
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf	Primary		Approved 7997	ARCAPTA Approved Use INDICATIONS AND USAGE. ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ARCAPTA NEOHALER is NOT indicated for asthma. Launch Date 1.29427204E12

C_max

Value	Dose	Co-administered	Analyte	Population
528 pg/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
339 pg/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.206 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.518 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.299 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.697 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2750 pg × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
907 pg × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.974 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.51 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
116 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
118 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	Disc. AE: Dyspnea, Wheezing... AEs leading to discontinuation/dose reduction: Dyspnea (serious, 1 patient) Wheezing (serious, 1 patient) Asthma (moderate, 1 patient) Cough (moderate, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	unhealthy Health Status: unhealthy Condition: asthma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf

AEs

AE	Significance	Dose	Population
Asthma	moderate, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Cough	moderate, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Dyspnea	serious, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Wheezing	serious, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Adverse event	grade 5	75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	unhealthy Health Status: unhealthy Condition: asthma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1470	substrate 865 inhibitor 1318	substrate 1038 inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 761 CYP3A4/5 225 CYP1A2 1268 CYP2C8 761 CYP2C19 1215 P-gp 1089 MRP2 341 BCRP 574 hOCT1 8	UGT1A1 358 UGT1A3 358 UGT1A4 295 UGT1A6 258 UGT1A8 242 UGT1A9 327 UGT1A10 247 UGT2B7 329 UGT2B15 165 CYP1A1 302 CYP1A2 892 CYP1B1 82 CYP2A6 452 CYP2B6 575 CYP2C8 586 CYP2C18 143 CYP2C19 830 CYP2E1 567 CYP3A5 346 CYP4A11 90 P-gp 1223	P-gp 225 MRP2 100

Drug as perpetrator

Target	Modality	Activity
MRP2 421	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	negligible
P-gp 1255	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	negligible
CYP2C9 1362	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
CYP2E1 841	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
CYP3A4/5 277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
BCRP 639	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
MRP2 421	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
P-gp 1255	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
hOCT1 8	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
CYP1A2 1406	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 10 uM]
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 25 uM]
CYP2C8 810	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 25 uM]
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 5 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A5 346	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=98 Page: 98.0	likely
CYP1A1 302	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	low
CYP2D6 1038	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	low
CYP1A2 892	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP1B1 82	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2A6 452	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2B6 575	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C18 143	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C19 830	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C8 586	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C9 865	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2E1 567	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP4A11 90	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A10 247	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A3 358	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A4 295	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A6 258	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A8 242	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A9 327	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT2B15 165	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT2B7 329	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
P-gp 1223	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak	yes (co-administration study) Comment: Co-administration of indacaterol with verapamil (P-gp inhibitor) showed 2 fold increase in indacaterol AUC0-24, and 1.5-fold increase in indacaterol Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0
UGT1A1 358	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	yes	weak (pharmacogenomic study) Comment: Nonsignificant trends toward higher Cmax and AUC0-24 (19% and 20%, respectively) were noted in patients with the (TA)7 genotype Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0
CYP3A4 1470	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	yes	yes (co-administration study) Comment: Co-administration of indacaterol with erythromycin (CYP3A4 inhibitor) showed a 1.4-fold increase in indacaterol AUC0-24, and 1.2-fold increase in indacaterol Cmax; Co-administration of indacaterol with ketoconazole caused a 1.9-fold increase in indacaterol AUC0-24, and 1.3-fold increase in indacaterol Cmax; Co-administration of indacaterol with ritonavir resulted in a 1.7-fold increase in indacaterol AUC0-24 whereas indacaterol Cmax was unaffected. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000PharmR.pdf#page=46 Page: 46.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:68575	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68575
ChemicalBook	CB72566367	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72566367
ChemicalBook	CB82512068	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82512068
MolPort	MolPort-023-219-171	https://www.molport.com/shop/molecule-link/MolPort-023-219-171
ZINC	ZINC000035801098	http://zinc15.docking.org/substances/ZINC000035801098

PubMed

Title	Date	PubMed
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease.	2005 Jul	16022567
Gateways to clinical trials.	2006 Dec	17235418
Indacaterol Novartis/skyePharma.	2006 May	16729723
In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.	2006 May	16434564
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.	2007 Dec	18219838
Gateways to clinical trials.	2007 Dec	18200333
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.	2007 Dec	17999782
Gateways to clinical trials.	2007 Jan-Feb	17344945
Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.	2007 Mar	17135231
Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.	2007 May	17251236
Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.	2007 Oct	17643277
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.	2008 Dec	19085578
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.	2008 Jan	18053019
Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.	2008 Jan	17916760
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.	2008 Jul	18681090
A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.	2008 Nov-Dec	18652905
Gateways to clinical trials.	2009 Apr	19536362
Bronchodilator effects of indacaterol and formoterol in patients with COPD.	2009 Dec	19465142
Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder.	2009 Dec	19449014
Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?	2009 Dec 8	19819331
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.	2009 Feb	19192991
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.	2009 Jul	19609496
Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma.	2009 May	19392928
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol.	2009 Oct	19650753
Gateways to clinical trials.	2009 Sep	19907722
Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.	2009 Sep	19422388
[Efficacy and safety of indacaterol - new long-acting beta(2) agonist].	2010	20461692
Impact of bronchodilator therapy on exercise tolerance in COPD.	2010 Apr 7	20463947
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.	2010 Dec	21166630
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.	2010 Dec	20978028
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.	2010 Dec	20850959
Novel bronchodilators in asthma.	2010 Jan	19816179
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.	2010 Jul 15	20463178
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.	2010 Jun	20522841
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.	2010 Jun	20080201
Indacaterol for chronic obstructive pulmonary disease (COPD).	2010 Mar	20467588
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.	2010 Mar	20411368
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.	2010 Mar 8	20211002
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.	2010 May 13	20402514
Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol.	2010 Nov	20843166
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.	2010 Nov	20619623
[Indacaterol is a new once-daily beta2-agonist for treatment of COPD].	2010 Nov 22	21092722
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.	2010 Oct 29	21034447
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.	2010 Oct 5	20920365
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.	2010 Sep 7	20856830
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.	2012 Oct 1	22932315
Metabolism and pharmacokinetics of indacaterol in humans.	2012 Sep	22648561
Emerging Therapeutic Options for the Management of COPD.	2013	23641160

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.

Route of Administration: Respiratory

In Vitro Use Guide

In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)

Name

Type

Language

INDACATEROL MALEATE

Official Name

English

INDACTEROL MALEATE

Common Name

English

QVA-149 COMPONENT INDACATEROL MALEATE

Common Name

English

ARCAPTA NEOHALER

Brand Name

English

INDACATEROL (AS MALEATE)

Common Name

English

2(1H)-QUINOLINONE, 5-((1R)-2-((5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-HYDROXYETHYL )-8-HYDROXY-, (2Z)-2-BUTENEDIOATE (1:1)

Common Name

English

QABI49

Code

English

INDACATEROL MALEATE [MI]

Common Name

English

INDACATEROL MALEATE [EMA EPAR]

Common Name

English

INDACATEROL MALEATE [WHO-DD]

Common Name

English

INDACATEROL MALEATE [ORANGE BOOK]

Common Name

English

ULTIBRO COMPONENT INDACATEROL MALEATE

Brand Name

English

INDACATEROL MALEATE [MART.]

Common Name

English

INDACATEROL MALEATE COMPONENT OF UTIBRON

Brand Name

English

QAB149-AFA

Code

English

INDACATEROL MALEATE [JAN]

Common Name

English

QAB-149-AFA

Code

English

INDACATEROL MALEATE [USAN]

Common Name

English

5-((1R)-2-((5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-HYDROXYETHYL)-8- HYDROXYQUINOLIN-2(1H)-ONE HYDROGEN (2Z)-2-BUTENEDIOATE (SALT)

Common Name

English

QVA149 COMPONENT INDACATEROL MALEATE

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

OSLIF BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)